Catatonic schizophrenia was once a formal psychiatric diagnosis describing a subtype of schizophrenia marked by severe disturbances in movement, speech, and behavior. It no longer exists as a standalone diagnosis. In 2013, the American Psychiatric Association removed “schizophrenia, catatonic type” from its diagnostic manual and reclassified catatonia as a specifier, a descriptor that can be added to many different psychiatric and medical conditions. This change reflected decades of evidence showing that catatonia occurs just as often in mood disorders and medical illnesses as it does in schizophrenia.
Why the Diagnosis Changed
From 1952 through 1994, every edition of the Diagnostic and Statistical Manual (DSM) classified catatonia exclusively as a type of schizophrenia, coded as 295.2. That created a problem: clinicians were seeing catatonic episodes in people with bipolar disorder, major depression, autoimmune conditions, and metabolic disorders, but the diagnostic system offered no way to capture that. In 1994, the DSM-IV took a first step by adding “catatonia secondary to a medical condition.” The DSM-5, published in 2013, went further and eliminated the catatonic schizophrenia subtype entirely.
Today, catatonia is recognized as a specifier that can be applied across at least 10 primary diagnoses, including schizophrenia, major depression, and bipolar disorder. A person with schizophrenia can still develop catatonic features, but the diagnosis would be recorded as “schizophrenia with catatonia” rather than “catatonic schizophrenia.” The distinction matters because it shapes which treatments are tried first and how urgently the underlying cause is investigated.
How Common Catatonia Is in Schizophrenia
About 10% of acute psychiatric inpatients show signs of catatonia. Among people specifically diagnosed with schizophrenia, a large meta-analysis covering more than 20,000 patients across 33 studies found a pooled prevalence of 9.8%. That means roughly 1 in 10 people hospitalized with schizophrenia will experience catatonic features at some point. Mood disorders actually show higher rates, with catatonia prevalence ranging from 14% to 71% depending on the study and setting.
What Catatonia Looks and Feels Like
The DSM-5 defines catatonia as the presence of three or more symptoms from a specific list: catalepsy, waxy flexibility, stupor, agitation, mutism, negativism, posturing, mannerisms, stereotypies, grimacing, echolalia, and echopraxia. In practice, the most visible signs fall into two broad patterns.
The more common pattern is the “retarded” or withdrawn type. A person may become completely immobile and unresponsive, staring blankly ahead and refusing to speak or eat. In a study of 220 consecutive catatonic cases, immobility and mutism were each present in 97% of patients. Withdrawal and refusal to eat appeared in 91%, and a fixed, unblinking stare in 87%. Waxy flexibility, where a person’s limbs can be moved into a position by someone else and then remain frozen there like warm wax, appeared in about 27% of cases.
Less common but equally striking are repetitive behaviors: echolalia (automatically repeating what someone else says), echopraxia (mimicking another person’s movements), and verbigeration (repeating the same word or phrase over and over). These appeared in roughly 14% of cases each. Some people display negativism, an automatic resistance to any instruction or attempt to move them, which showed up in 67% of patients studied. There is also an “excited” form of catatonia involving purposeless, agitated movement that doesn’t appear to respond to anything in the environment.
What Happens in the Brain
Catatonia involves disruptions in the brain areas that control movement, decision-making, and emotional processing. The motor cortex, supplementary motor area, parietal cortex, and the front part of the prefrontal cortex are the regions most consistently linked to catatonic states. Changes in the amygdala and hypothalamus may drive the emotional and fear-related components, helping explain why some patients appear frozen in a state of extreme anxiety.
Three neurotransmitters play central roles. GABA, the brain’s primary calming chemical, appears to be underactive in the stuporous form of catatonia. Glutamate, an excitatory neurotransmitter, may be overactive, essentially overriding GABA’s ability to regulate movement. Dopamine dysfunction, already implicated in schizophrenia more broadly, adds another layer of disruption to the circuits that initiate and control voluntary movement. This GABA deficit is a key reason why certain sedative medications work so well as both a diagnostic test and a treatment.
How Catatonia Is Confirmed
Beyond observing the physical signs, clinicians use a benzodiazepine challenge to confirm the diagnosis. A dose of a fast-acting sedative (typically lorazepam) is given, and the patient is observed for improvement. When two or more catatonia signs have been present for more than 24 hours and at least 50% of those signs resolve after the medication, the diagnosis is confirmed. In one protocol studied, about two-thirds of patients became completely free of catatonic symptoms after a single 2 mg dose.
Before confirming catatonia, other conditions that can look remarkably similar need to be ruled out. These include Parkinson’s disease (which also causes rigid, slow movement), stiff-person syndrome, malignant hyperthermia, locked-in syndrome, and conversion disorder. Brain imaging is typically done to exclude structural damage from a stroke, tumor, or abscess. Metabolic problems like severely low sodium levels and substance-induced states can also mimic catatonia and must be investigated.
Treatment and Response Rates
The first-line treatment for catatonia, regardless of its underlying cause, is a benzodiazepine. Lorazepam is the most commonly used, and many patients respond within hours to days. This rapid response is one of the features that distinguishes catatonia from other severe psychiatric states and is part of why recognizing it quickly matters so much.
For people who don’t respond adequately to benzodiazepines, electroconvulsive therapy (ECT) is highly effective. Response rates for ECT in catatonia range from 80% to 100%. In one study, 19 of 20 patients achieved a response, with the average number of sessions needed being just over four. ECT works on catatonia associated with schizophrenia, mood disorders, and medical conditions alike.
Treating the underlying condition is equally important. If the catatonia is occurring alongside schizophrenia, antipsychotic medications may be adjusted, though some older antipsychotics can actually worsen catatonia or trigger a dangerous reaction called neuroleptic malignant syndrome. This is another reason the reclassification away from “catatonic schizophrenia” was clinically significant: it encouraged clinicians to treat the catatonia itself first, rather than reflexively increasing antipsychotic doses.
Physical Risks of Prolonged Catatonia
Catatonia is a medical emergency when it involves complete immobility and refusal to eat or drink. Prolonged stillness puts patients at risk for deep vein thrombosis (blood clots in the legs) and pulmonary embolism, where a clot travels to the lungs. These complications can be fatal and are sometimes overlooked because clinicians focus on the more obvious concerns of dehydration and decreased urine output.
Other serious complications include malnutrition, pressure ulcers from lying in one position, aspiration pneumonia from difficulty swallowing, and rhabdomyolysis, a breakdown of muscle tissue that can damage the kidneys. The combination of negativism, immobility, and refusal to take in fluids creates a cascade of risks that makes prompt recognition and treatment of catatonia genuinely lifesaving.